---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125340"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:41:51.910721+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eledon completes BESTOW enrollment early; reports $77M net income on non-cash gain

## Summary
- Phase 2 BESTOW trial for tegoprubart in kidney transplant hit target of 120 patients ~4 months ahead of schedule.
- First two islet transplant recipients with type 1 diabetes achieved insulin independence on tegoprubart without tacrolimus.
- Completed oversubscribed $85M offering in October; net proceeds ~$79.5M extend cash runway to end of 2026.
- Q3 2024 net income $77M ($1.05 basic EPS) includes $96.4M non-cash fair value gain; adjusted net loss $19.5M.
- Cash and short-term investments $78.2M at Sep 30, 2024; R&D expenses rose to $16.5M from $7.9M YoY.

## SEC filing metadata
- accession: 0000950170-24-125340
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017024125340/0000950170-24-125340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017024125340/eldn-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125340
- JSON: https://secwatch.observer/filing/0000950170-24-125340.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.